Kriya's Series C Surges to Over $430 Million

Palo Alto, CA, and Research Triangle Park, NC, July 26, 2023 (Globe Newswire) -- Kriya Therapeutics, Inc., a biopharmaceutical company pioneering transformation gene therapies in opthalmology, Neurology and metabolic disease, announced a $150 million infusion in its Series C Financing. This boost elevates the total Series C round to $430 million, reinforcing Kriya's commitment to transforming the lives of millions worldwide.

Read full article here.